{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:12:35Z","timestamp":1790205155193,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"DOI":"10.7759\/cureus.96076","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:02:51Z","timestamp":1762264971000},"source":"Crossref","is-referenced-by-count":2,"title":["Association of Tumor-Infiltrating Lymphocytes (TILs) With Pathological Complete Response to Neoadjuvant Therapy in\u00a0Breast\u00a0Cancer"],"prefix":"10.7759","author":[{"given":"Noor","family":"Ul Ain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ishaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Khurrum","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quratulain","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhair Abbas","family":"Bangash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001814","article-title":"Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019","volume":"135","author":"Luo C","year":"2022","unstructured":"Luo C, Li N, Lu B, et al.. Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019. Chin Med J (Engl). 2022, 135:42-51. 10.1097\/CM9.0000000000001814","journal-title":"Chin Med J (Engl)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2274483","article-title":"Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer","volume":"62","author":"Land\u00e9n AH","year":"2023","unstructured":"Land\u00e9n AH, Chin K, Kov\u00e1cs A, et al.. Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer. Acta Oncol. 2023, 62:1862-72. 10.1080\/0284186X.2023.2274483","journal-title":"Acta Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.02.002","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, et al.. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025, 5:287-96. 10.1016\/j.jncc.2025.02.002","journal-title":"J Natl Cancer Cent"},{"key":"ref4","article-title":"Breast cancer in pakistan - awareness and early detection","volume":"17","author":"Sohail S","year":"2007","unstructured":"Sohail S, Alam SN. Breast cancer in pakistan - awareness and early detection. J Coll Physicians Surg Pak. 2007, 17:711-2.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.32350\/cto.42.01","article-title":"Current situation of breast cancer in Pakistan and the dire need of early diagnosis","volume":"4","author":"Khan NU","year":"202420","unstructured":"Khan NU, Khan BM, Azam I, Hayat A. Current situation of breast cancer in Pakistan and the dire need of early diagnosis. Curr Trends OMICS. 202420, 4:1-20. 10.32350\/cto.42.01","journal-title":"Curr Trends OMICS"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/11782234211025346","article-title":"Breast cancer awareness and associated factors amongst women in Peshawar, Pakistan: a cross-sectional study","volume":"15","author":"Ullah Z","year":"2021","unstructured":"Ullah Z, Khan MN, Din ZU, Afaq S. Breast cancer awareness and associated factors amongst women in Peshawar, Pakistan: a cross-sectional study. Breast Cancer (Auckl). 2021, 15:11782234211025346. 10.1177\/11782234211025346","journal-title":"Breast Cancer (Auckl)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36517-2","article-title":"Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer","volume":"13","author":"Qian XL","year":"2023","unstructured":"Qian XL, Xia XQ, Li YQ, et al.. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer. Sci Rep. 2023, 13:9256. 10.1038\/s41598-023-36517-2","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i7.920","article-title":"Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: a systematic review and meta-analysis","volume":"15","author":"Sun HK","year":"2024","unstructured":"Sun HK, Jiang WL, Zhang SL, Xu PC, Wei LM, Liu JB. Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: a systematic review and meta-analysis. World J Clin Oncol. 2024, 15:920-35. 10.5306\/wjco.v15.i7.920","journal-title":"World J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07334-6","article-title":"Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study","volume":"207","author":"Chin K","year":"2024","unstructured":"Chin K, Land\u00e9n AH, Kov\u00e1cs A, W\u00e4rnberg F, Ekholm M, Karlsson P, Olofsson Bagge R. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study. Breast Cancer Res Treat. 2024, 207:49-63. 10.1007\/s10549-024-07334-6","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105866","article-title":"Tumor infiltrating lymphocytes in breast cancer: a narrative review with focus on analytic validity, clinical validity, and clinical utility","volume":"162","author":"Finkelman BS","year":"2025","unstructured":"Finkelman BS, Zhang H, Hicks DG, Rimm DL, Turner BM. Tumor infiltrating lymphocytes in breast cancer: a narrative review with focus on analytic validity, clinical validity, and clinical utility. Hum Pathol. 2025, 162:105866. 10.1016\/j.humpath.2025.105866","journal-title":"Hum Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/gs-2024-537","article-title":"Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer","volume":"14","author":"Zhao Y","year":"2025","unstructured":"Zhao Y, Jiang SJ, Wang JL, Xie ZY, Jin X. Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer. Gland Surg. 2025, 14:628-45. 10.21037\/gs-2024-537","journal-title":"Gland Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104687","article-title":"Impact of tumor-infiltrating lymphocytes (TILs) on the pathological complete response (pCR) after neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer","volume":"10","author":"Zakaria DA","year":"2025","unstructured":"Zakaria DA. Impact of tumor-infiltrating lymphocytes (TILs) on the pathological complete response (pCR) after neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer. ESMO Open. 2025, 10:10.1016\/j.esmoop.2025.104687","journal-title":"ESMO Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf054","article-title":"Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer","volume":"30","author":"K\u0131n\u0131ko\u011flu O","year":"2025","unstructured":"K\u0131n\u0131ko\u011flu O, Alt\u0131nta\u015f YE, Y\u0131ld\u0131z A, et al.. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer. Oncologist. 2025, 30:10.1093\/oncolo\/oyaf054","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01999-7","article-title":"Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER\u2009+\u2009HER2- breast cancer","volume":"27","author":"Baek SH","year":"2025","unstructured":"Baek SH, Lee MJ, Kook Y, Bae SJ, Jeong J, Cha YJ, Ahn SG. Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER\u2009+\u2009HER2- breast cancer. Breast Cancer Res. 2025, 27:42. 10.1186\/s13058-025-01999-7","journal-title":"Breast Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al.. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018, 19:40-50. 10.1016\/S1470-2045(17)30904-X","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-23-43","article-title":"Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives","volume":"5","author":"Rosa ML","year":"2024","unstructured":"Rosa ML, Reinert T, Pauletto MM, Sartori G, Graudenz M, Barrios CH. Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives. Transl Breast Cancer Res. 2024, 5:4. 10.21037\/tbcr-23-43","journal-title":"Transl Breast Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999843","article-title":"Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis","volume":"12","author":"Zhu Y","year":"2022","unstructured":"Zhu Y, Tzoras E, Matikas A, Bergh J, Valachis A, Zerdes I, Foukakis T. Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. Front Oncol. 2022, 12:999843. 10.3389\/fonc.2022.999843","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01708-7","article-title":"Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group","volume":"126","author":"Almangush A","year":"2022","unstructured":"Almangush A, Jouhi L, Atula T, Haglund C, M\u00e4kitie AA, Hagstr\u00f6m J, Leivo I. Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br J Cancer. 2022, 126:1589-94. 10.1038\/s41416-022-01708-7","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.933113","article-title":"Stromal and immune cell dynamics in tumor associated tertiary lymphoid structures and anti-tumor immune responses","volume":"10","author":"Rossi A","year":"2022","unstructured":"Rossi A, Belmonte B, Carnevale S, et al.. Stromal and immune cell dynamics in tumor associated tertiary lymphoid structures and anti-tumor immune responses. Front Cell Dev Biol. 2022, 10:933113. 10.3389\/fcell.2022.933113","journal-title":"Front Cell Dev Biol"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, et al.. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015, 26:259-71.","journal-title":"Ann Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-558","article-title":"St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial","volume":"13","author":"Falck AK","year":"2013","unstructured":"Falck AK, Fern\u00f6 M, Bendahl PO, Ryd\u00e9n L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer. 2013, 13:558. 10.1186\/1471-2407-13-558","journal-title":"BMC Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2019.22.e49","article-title":"Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy","volume":"22","author":"Li X","year":"2019","unstructured":"Li X, Wang M, Wang M, et al.. Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy. J Breast Cancer. 2019, 22:497-521. 10.4048\/jbc.2019.22.e49","journal-title":"J Breast Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163876","article-title":"Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine","volume":"14","author":"Derouane F","year":"2022","unstructured":"Derouane F, van Marcke C, Berli\u00e8re M, et al.. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers (Basel). 2022, 14:10.3390\/cancers14163876","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo A","year":"2022","unstructured":"Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2022, 31:549-55. 10.1080\/13543784.2022.2008354","journal-title":"Expert Opin Investig Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.001","article-title":"Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis","volume":"66","author":"Li S","year":"2022","unstructured":"Li S, Zhang Y, Zhang P, Xue S, Chen Y, Sun L, Yang R. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis. Breast. 2022, 66:97-109. 10.1016\/j.breast.2022.10.001","journal-title":"Breast"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka A","year":"2024","unstructured":"Ciarka A, Pi\u0105tek M, P\u0119ksa R, Kunc M, Senkus E. Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes. Biomedicines. 2024, 12:10.3390\/biomedicines12040763","journal-title":"Biomedicines"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00636-4","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade","volume":"10","author":"Liefaard MC","year":"2024","unstructured":"Liefaard MC, van der Voort A, van Seijen M, et al.. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. NPJ Breast Cancer. 2024, 10:29. 10.1038\/s41523-024-00636-4","journal-title":"NPJ Breast Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre RA","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, et al.. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024, 331:1135-44. 10.1001\/jama.2024.3056","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162895","article-title":"Tumor-infiltrating lymphocyte scoring in neoadjuvant-treated breast cancer","volume":"16","author":"Thomas N","year":"2024","unstructured":"Thomas N, Garaud S, Langouo M, et al.. Tumor-infiltrating lymphocyte scoring in neoadjuvant-treated breast cancer. Cancers (Basel). 2024, 16:10.3390\/cancers16162895","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4274\/ejbh.galenos.2023.2023-11-2","article-title":"Factors affecting pathological complete response in locally advanced breast cancer cases receiving neoadjuvant therapy: a comprehensive literature review","volume":"27","author":"Alamoodi M","year":"2023","unstructured":"Alamoodi M. Factors affecting pathological complete response in locally advanced breast cancer cases receiving neoadjuvant therapy: a comprehensive literature review. Eur J Breast Health. 2023, 27:8-14. 10.4274\/ejbh.galenos.2023.2023-11-2","journal-title":"Eur J Breast Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419494-association-of-tumor-infiltrating-lymphocytes-tils-with-pathological-complete-response-to-neoadjuvant-therapy-inbreastcancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:02:51Z","timestamp":1762264971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419494-association-of-tumor-infiltrating-lymphocytes-tils-with-pathological-complete-response-to-neoadjuvant-therapy-inbreastcancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.96076","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}